Treatment options for female sexual arousal disorder: part II.
Female sexual arousal disorder (FSAD) occurs when a woman experiences distress due to the inability to attain or maintain adequate vaginal lubrication. Many treatments are still under investigation, and at this time, there are no FDA-approved medications available for the treatment of FSAD. Treatment options include "off-label" medications, vaginal estrogen, compounded preparations, and over-the-counter products.
Feldhaus-Dahir
Melissa
M
Sexual Medicine & Wellness Center, Methodist Physicians Women's Clinic, Omaha, NE, USA.
D000282:Administration, Intravaginal; D058669:Adrenergic alpha-2 Receptor Antagonists / Q000627:therapeutic use; D000527:Alprostadil / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006027:Glycosides / Q000627:therapeutic use; D006801:Humans; D054327:Lubricants; D008903:Minerals / Q000627:therapeutic use; D004366:Nonprescription Drugs / Q000627:therapeutic use; D056687:Off-Label Use; D010879:Piperazines / Q000627:therapeutic use; D028321:Plant Preparations / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000209:etiology / Q000517:prevention & control*; D020018:Sexual Dysfunctions, Psychological / Q000209:etiology / Q000517:prevention & control*; D000068677:Sildenafil Citrate; D013396:Suction; D013450:Sulfones / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D015016:Yohimbine / Q000627:therapeutic use
D058669:Adrenergic alpha-2 Receptor Antagonists; C117405:ArginMax; D006027:Glycosides; D054327:Lubricants; D008903:Minerals; D004366:Nonprescription Drugs; D010879:Piperazines; D028321:Plant Preparations; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D015016:Yohimbine; D000068677:Sildenafil Citrate; D000527:Alprostadil